Sept 22nd
Upcoming Webinars
Discover the future of thyroid care with RenThyroid. This webinar will dive into the clinical applications and protocols for using RenThyroid in your practice. Enhance your knowledge and stay ahead in offering top-tier thyroid treatment to your patients.
RenThyroid Public Education Masterclass
Join thyroid expert McCall McPherson, PA-C, for a live masterclass designed for healthcare professionals. This session will provide clinical insights into thyroid symptom management and highlight how RenThyroid, a new thyroid therapy, is improving patient outcomes and helping restore quality of life.
What is Natural Desiccated Thyroid?
Natural desiccated thyroid (NDT) is a natural medication used to support patients with hypothyroidism. Unlike synthetic thyroid hormone treatments, which only contain T4 (thyroxine), NDT provides both T3 (triiodothyronine) and T4.
Meet McCall
McPherson, PA-C
Paid Consultant for RenThyroid
McCall McPherson is a pioneering physician associate and entrepreneur in thyroid, hormone, and metabolic health. As founder of Modern Thyroid Clinic, she combines medical expertise with personal experience to offer innovative solutions as well as a unique and balanced approach to wellness. A TEDx speaker, honored in the Top 200 Fastest Growing Health Companies on 2024’s Inc 5000 list, a 2025 Top 500 Inc Female Founder and the host of the podcast Modern Thyroid & Wellness.
Patients on NDT therapy also noted improvements in common symptoms of hypothyroidism:*
Concentration, memory and decision-making
Mental well-being and mood
Weight loss
Sleep
Energy
*Measured by the general health questionnaire (GHQ-12) and thyroid symptom questionnaire (TSQ).
References:
[1] Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism Prevalence in the United States: A Retrospective Study Combining National Health and Nutrition Examination Survey and Claims Data 2009-2019. J Endoc Soc. 2022 Nov 17; 7(1): bvac172. doi: 10.120/jendso/bvac172.
[2] McAninch EA, Bianco AC. The swinging pendulum in treatment for hypothyroidism: from (and toward?) combination therapy. Front Endocrinol. 2019;10:446. doi:10.3389/fendo.2019.00446
[3] Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MKM. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study; J Clin Endocrinol Metab. 2013;98(5):1982-1990. doi:10.1210/jc.2012-4107
[1] Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism Prevalence in the United States: A Retrospective Study Combining National Health and Nutrition Examination Survey and Claims Data 2009-2019. J Endoc Soc. 2022 Nov 17; 7(1): bvac172. doi: 10.120/jendso/bvac172.
[2] McAninch EA, Bianco AC. The swinging pendulum in treatment for hypothyroidism: from (and toward?) combination therapy. Front Endocrinol. 2019;10:446. doi:10.3389/fendo.2019.00446
[3] Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MKM. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study; J Clin Endocrinol Metab. 2013;98(5):1982-1990. doi:10.1210/jc.2012-4107
RenThyroid® (Thyroid Tablets, USP) is a prescription oral medication indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.
Note: RenThyroid has not been reviewed by the FDA for safety or efficacy.
IMPORTANT SAFETY INFORMATION:
DRUGS WITH THYROID HORMONE ACTIVITY, ALONE OR TOGETHER WITH OTHER THERAPEUTIC AGENTS, HAVE BEEN USED FOR THE TREATMENT OF OBESITY. IN EUTHYROID PATIENTS, DOSES WITHIN THE RANGE OF DAILY HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION. LARGER DOSES MAY PRODUCE SERIOUS OR EVEN LIFE-THREATENING MANIFESTATIONS OF TOXICITY, PARTICULARLY WHEN GIVEN IN ASSOCIATION WITH SYMPATHOMIMETIC AMINES SUCH AS THOSE USED FOR THEIR ANORECTIC EFFECTS.
CONTRAINDICATIONS:
RenThyroid is contraindicated in patients with uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and/or hypersensitivity to any component of the product.
WARNINGS AND PRECAUTIONS:
Cardiovascular System. Thyroid hormones should be used with caution in the presence of cardiovascular risks, and particularly coronary artery risks. Patients with angina pectoris and elderly patients present increased risks. Initiate treatment with low doses (15-30 mg). Worsening cardiovascular disease may require reduced dose or discontinuation.
Diabetes and Adrenal Disorders. In patients with concomitant diabetes mellitus, diabetes insipidus, or adrenal cortical insufficiency, thyroid hormones aggravate symptoms of these conditions. Adjust treatment for these concomitant endocrine diseases as appropriate. Treatment of myxedema coma requires simultaneous administration of glucocorticoids.
Oral Anticoagulants. Hypothyroidism decreases and hyperthyroidism increases sensitivity to oral anticoagulants. For patients taking thyroid hormones and oral anticoagulants, prothrombin time and dose should be closely monitored and adjusted based on frequent prothrombin time determinations.
Infant Craniosynostosis. In infants, excessive doses of thyroid hormones may produce craniosynostosis.
ADVERSE REACTIONS:
Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare. Excessive doses of thyroid result in a hypermetabolic state. In case of overdosage, temporarily discontinue treatment. Treatment may be reinstituted at a lower dosage.
DRUG INTERACTIONS:
Oral Anticoagulants. Concomitant use of thyroid hormones with oral anticoagulants alters the sensitivity of oral anticoagulants.
Insulin or Oral Hypoglycemics. Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. Patients receiving insulin or oral hypoglycemics should be closely monitored during initiation of thyroid replacement therapy.
Cholestyramine or Colestipol. Cholestyramine or colestipol binds both levothyroxine (T4) and liothyronine (T3) in the intestine, impairing their absorption. Allow 4 to 5 hours between the administration of cholestyramine or colestipol and thyroid hormones.
Estrogen, Oral Contraceptives. Estrogens tend to increase serum thyroxine-binding globulin (TBg), decreasing free levothyroxine (T4). Patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if taking estrogen or estrogen-containing oral contraceptives.
Drug/Laboratory Test Interactions. Certain drugs or moieties interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations, biotin, and preparations containing salicylates.
For complete safety information, including Boxed Warning, please see the full Prescribing Information linked here.
To report suspected adverse reactions, contact Genus Lifesciences at 1-610-782-9780 or Info@GenusLifesciences.com or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.